Ayumi Kaneda

The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.

Ayumi Kaneda, Toshihiro Seike, Tomohiro Danjo et al. · PubMed · 2020 · 148 citations · Full text

Pathology, Organ Development, Cancer Biology +20

Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone

Masatoshi Takeiri, Miyuki Tachibana, Ayumi Kaneda et al. · Inflammation Research · 2011 · 31 citations

Inflammation, Macrophage Activation, Medicine +8

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

Hiroji Iwata, Rikiya Nakamura, Norikazu Masuda et al. · Japanese Journal of Clinical Oncology · 2022 · 14 citations · Full text

Inhibition of RANKL- and LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide

Naoki Koide, Ayumi Kaneda, Takashi Yokochi et al. · International Immunopharmacology · 2015 · 11 citations

Abstract 3086: Discovery of a <i>first-in-class</i> TEAD inhibitor which directly inhibits YAP/TAZ-TEAD protein-protein interaction and shows a potent anti-tumor effect in malignant pleural mesothelioma

Ayumi Kaneda, Toshihiro Seike, Takeshi Uemori et al. · Cancer Research · 2019 · 11 citations

Yap/taz-tead Protein-protein Interaction, Mpm Cell Lines, Hippo Pathway +15